REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-02. Numbers and descriptions here follow the published literature rather than marketing material.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Gemma Clair Collins (born 31 January 1981) is an English media personality and businesswoman. She rose to prominence whilst appearing on the ITV reality series The Only Way Is Essex (2011–2019) and went on to appear on various other reality television shows, including I'm a Celebrity...Get Me Out of Here! (2014), Celebrity Big Brother (2016), Celebs Go Dating (2018) and Dancing on Ice (2019). Known for her diva persona and alter-ego "the GC", she became the subject of several internet memes and is considered a prominent figure within the British hun subculture. A sales executive by trade, Collins created her own plus-size clothing brand and owned a fashion boutique in Brentwood, Essex, as well as releasing a fragrance and a line of cosmetics. She has also collaborated with numerous brands to endorse their products alongside her own. Collins published two autobiographies and starred in her own ITV reality television franchise Gemma Collins: Diva (2018–2020). She went on to host the eponymous The Gemma Collins Podcast (2019–2024), as well as its spin-off The Gemma Collins Love Lounge (2020–2021). In 2022, she fronted a Channel 4 television documentary, Gemma Collins: Self-Harm & Me, based on her personal experiences and embarked on a theatre tour, The GC's Big Night Out. In 2026, she appeared as a contestant on the second series of I'm a Celebrity... South Africa and is set to star in the Sky One reality series Gemma Collins: Everything. All At Once.
Development of facial wrinkles is a kind of fibrosis of the skin. Misrepair-accumulation aging theory suggests that wrinkles develop from incorrect repairs of injured elastic fibers and collagen fibers. Repeated extensions and compressions of the skin cause repeated injuries of extracellular fibers in derma. During the repairing process, some of the broken elastic fibers and collagen fibers are not regenerated and restored but replaced by altered fibers. When an elastic fiber is broken in an extended state, it may be replaced by a "long" collagen fiber. Accumulation of "long" collagen fibers makes part of the skin looser and stiffer, and as a consequence, a big fold of skin appears. When a "long" collagen is broken in a compressed state, it may be replaced by a "short" collagen fiber. The "shorter" collagen fibers will restrict the extension of "longer" fibers, and make the "long" fibers in a folding state permanently. A small fold, namely a permanent wrinkle, then appears.
=== Synthetic scaffolds === The use of natural materials in scaffolds has its disadvantages. Usually, they are expensive, not available in large quantities and they have the risk of disease transmission. This has led to the development of synthetic scaffolds. When producing synthetic scaffolds there is full control over their properties. For example, they can be made to have good mechanical properties and the right biodegradability. When it comes to synthetic scaffolds thickness, porosity and pore size are important factors for controlling connective tissue formation. Examples of synthetic scaffolds are:
=== GamerGate === In 2014, Baldwin became associated with GamerGate after using the hashtag "#GamerGate" during the controversy. Sources differed on how to characterize his role in the hashtag's origin: Time wrote that Baldwin "coined" the term, The Washington Post reported that its origin was disputed and that Baldwin claimed credit for it, and The New Yorker described it as having been popularized by him. The New Yorker also reported that Baldwin linked to a video making an allegation about game developer Zoë Quinn that the magazine said had since been "proved false". In a 2014 interview with Vulture, Baldwin described GamerGate as focused on ethics in games journalism and argued that threats of violence should not be treated as inherent to the hashtag, calling it "a mistake to commingle the two". WIRED later described Baldwin as lending "high profile support" to the controversy, while the Columbia Journalism Review wrote that, in the absence of clear spokespeople for GamerGate, journalists sometimes interviewed "proxies like actor Adam Baldwin".
According to Reuters, the conflict involving Iran has resulted in increased oil prices, elevated inflation rates, and a subsequent rise in the cost of living within the United States. Furthermore, a majority of voters in 2025 report experiencing a decline in their economic well-being under the administration of President Trump.
Sources: en.wikipedia.org
The carbon footprint of cattle rearing (see environmental impact of meat production) Use of chemicals in the tanning process (e.g., chromium, phthalate esters, nonyl phenol ethoxylate soaps, pentachlorophenol and solvents) Air pollution due to the transformation process (hydrogen sulfide is formed during mixing with acids and ammonia liberated during deliming, solvent vapors)
== Epidemiology == In 2010, poisoning resulted in about 180,000 deaths down from 200,000 in 1990. There were approximately 727,500 emergency department visits in the United States involving poisonings—3.3% of all injury-related encounters.
Although districts are not formally designated by income, areas closer to the city center, metro stations, or green zones are considered more prestigious. Moscow also contains some government bodies of the Moscow Oblast, although the city is not part of the oblast.
As astrocytes are increasingly recognized as active contributors to several neurological disorders and potential therapeutic targets, researchers are investigating how these cells can be monitored or modulated using emerging neurotechnologies. For example, a recent in vitro study (2025) reported that physiologically relevant concentrations of Ti3C2Tx MXene flakes, a promising two-dimensional nanomaterial for glial-targeted neural interfaces, were biocompatible with astrocytes and did not alter cell viability, morphology, or spontaneous calcium signaling. Research in this area aims to investigate how astrocytes interact with emerging neurotechnologies and engineered materials, which is increasingly important as tools for understanding and modulating brain function continue to advance.
== Alternative pathway == Plants, most bacteria, and some protozoa such as malaria parasites have the ability to produce isoprenoids using an alternative pathway called the methylerythritol phosphate (MEP) or non-mevalonate pathway. The output of both the mevalonate pathway and the MEP pathway are the same, IPP and DMAPP; however, the enzymatic reactions to convert acetyl-CoA into IPP are entirely different. Interaction between the two metabolic pathways can be studied by using 13C-glucose isotopomers. In higher plants, the MEP pathway operates in plastids while the mevalonate pathway operates in the cytosol. Examples of bacteria that contain the MEP pathway include Escherichia coli and pathogens such as Mycobacterium tuberculosis.
Sources: en.wikipedia.org
Committee on Armed Services Subcommittee on Cybersecurity Subcommittee on Emerging Threats and Capabilities Subcommittee on Seapower Committee on Commerce, Science, and Transportation Subcommittee on Space and Science (Ranking Member) Subcommittee on Communications, Media, and Broadband Subcommittee on Surface Transportation, Maritime, Freight, and Ports
A Scotch whisky label comprises several elements that indicate aspects of production, age, bottling, and ownership. Some of these elements are regulated by the SWR, and some reflect tradition and marketing. The spelling of the term whisky is often debated by journalists and consumers. Scottish, English, Welsh, Australian and Canadian whiskies use whisky, Irish whiskies use whiskey, while American and other styles vary in their spelling of the term. The label always features a declaration of the malt or grain whiskies used. A single malt Scotch whisky is one that is entirely produced from malt in one distillery. One may also encounter the term "single cask", signifying the bottling comes entirely from one cask. The term "blended malt" signifies that single malt whisky from different distilleries is blended in the bottle. The Cardhu distillery also began using the term "pure malt" for the same purpose, causing a controversy in the process over clarity in labelling—the Glenfiddich distillery was using the term to describe some single malt bottlings. As a result, the Scotch Whisky Association declared that a mixture of single malt whiskies must be labelled a "blended malt". The use of the former terms "vatted malt" and "pure malt" is prohibited. The term "blended malt" is still debated, as some bottlers maintain that consumers confuse the term with "blended Scotch whisky", which contains some proportion of grain whisky.
The two substrates of this enzyme are (–)-pipecolic acid and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are 1-piperideine-2-carboxylic acid, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-pipecolate:NADP+ 2-oxidoreductase. Other names in common use include 1,2-didehydropipecolate reductase, P2C reductase, and 1,2-didehydropipecolic reductase. This enzyme participates in lysine degradation.
=== Film adaptation === In February 2013, Valve president Gabe Newell and film director J. J. Abrams announced that they were to collaborate on a film adaptation of the Portal series. In 2016, Abrams stated that he still has plans to direct these films in the future, with both films in the writing stage. Abrams confirmed in May 2021 that the film adaptation was still in the works as they were still working on a script for the film from Warner Bros. Pictures. In 2026, Kane Parsons also expressed interest in directing a Portal film.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.